US/UK/Canada

Share

Contacts

  • Andreas Lindblom

    Managing Partner, Sciety


    Grev Turegatan 26 114 38 Stockholm Sweden
    +46 703 75 73 73
    http://www.sciety.se

    • Links

    Quotes

    Everdrone addresses a clear and well-documented need within emergency care. The company has established customer partnerships with several regions in Sweden and in France, and combines technological .depth with clinical relevance. As a long-term capital partner, we look forward to supporting Everdrone in its next phase of expansion
    Andreas Lindblom, Managing Partner, Sciety
    Neogap is at a stage where clear progress is combined with strong commercial potential in an area of significant unmet medical need. The company has a unique therapeutic approach to T-cell therapy, combining personalised treatment with a scalable manufacturing process. This is exactly the type of company we focus on when we invest and raise capital.
    Andreas Lindblom, Managing Partner, Sciety
    Rubicon Healthcare Partners’ investment in PeptiSystems is a clear validation of the company’s progress and market position. As a growth equity investor focused on Nordic life science companies, Rubicon will be an important partner in PeptiSystems’ next phase, benefiting both the company and existing shareholders. For us at Sciety, the investment confirms our ability to identify companies with leading technologies, experienced teams, and strong market potential.
    Andreas Lindblom, Managing Partner, Sciety
    Nick brings a rare combination of scientific expertise, international business experience and strategic insight. His strong background in building and leading global organisations makes him a valuable addition to PeptiSystems’ board. His experience will be particularly important as the company continues its international expansion and meets the growing global demand for advanced manufacturing solutions in the peptide and oligonucleotide field
    Andreas Lindblom, Managing Partner, Sciety
    Peder Walberg brings experience that complements the existing board in a highly valuable way. His strategic and commercial expertise is particularly important at this stage of the company’s journey – where making the right decisions around study design and regulatory strategy will lay the foundation for strong positioning and future commercialisation. Helping to identify the right board expertise is a key part of how we at Sciety work in close partnership with our portfolio companies
    Andreas Lindblom, Managing Partner, Sciety
    TIRmed Pharma has the potential to transform the treatment landscape for atopic dermatitis. They combine innovative technology with a strong team and a clear strategy – precisely what we seek in our investments. We look forward to following the company’s journey and supporting them in their continued development.
    Andreas Lindblom, Managing Partner at Sciety
    Sciety is happy to invest in Capitainer once again, together with the network Sciety Venture Partners. The company offers an entirely new way of providing blood samples, which could simplify the process for patients, especially those in need of regular monitoring. We see significant potential for the company to make a substantial impact on its market, with considerable benefits for both patients and healthcare providers.
    Andreas Lindblom, Managing Partner at Sciety
    Apart from strengthening the company financially, we are convinced that the investment from We Venture Capital will result in synergies which also will strengthen the company strategically in its work to position itself as a leading player in the self-sampling market.
    Andreas Lindblom, Managing Partner, Sciety
    We are delighted to once again invest in Neogap and thus be able to contribute to important advances in cancer treatment. The company has a unique approach that is based on the realisation that each cancer is unique and differs between different patients and tumors. By using proprietary algorithms for machine learning and patented technology to train the patient’s own T-cells to attack the cancer cells, the company develops a completely individualised treatment. The company’s first indication, colorectal cancer, is the second most common cause of cancer death, so there is a great medical need here.
    Andreas Lindblom, Managing Partner, Sciety
    Pick a time period -
    Tags ( Active)
    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media